All In Biotech

Drug Trial Radar · NCT01519778

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

Phase 2 Open-Label Safety and Exploratory Skin Lesion Measurement Study of 6-Day Oral TR-701 FA in Skin Abscess and Cellulitis Patients

Last checked: Nov 20, 2026Latest source record: Aug 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

200

Actual

Start

Feb 15, 2012

Primary completion

Aug 27, 2012

Study completion Aug 27, 2012

Sponsor

Sponsor type
Industry
Collaborators
Bayer
First posted
Jan 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.

Conditions

  • Major Cutaneous Abscess
  • Cellulitis
  • Erysipelas

Interventions

  • TR701 FADrug

    1 tablet 200 mg once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 24-31 days

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Trius Investigator Site #118

    Anaheim, California

  • Trius Investigator Site #129

    Buena Park, California

  • Trius Investigator Site 103

    Chula Vista, California

  • Trius Investigator Site 105

    La Mesa, California

  • Trius Investigator Site #106

    Long Beach, California

  • Trius Investigator Site 104

    Oceanside, California

  • Trius Investigator Site 101

    Columbus, Georgia

  • Trius Investigator Site 102

    Savannah, Georgia

  • Trius Investigator Site 128

    Las Vegas, Nevada

  • Trius Investigator Site 115

    Somers Point, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.